Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19594759,inhibition constant K(i),"Gaboxadol may be a substrate of the human proton-coupled amino acid transporter, hPAT1 and it inhibited the hPAT1-mediated L-[(3)H]proline uptake in Caco-2 cell monolayers with an inhibition constant K(i) of 6.6 mmol.L(-1).",Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19594759/),[mM] / [l],6.6,4413,DB00150,L-Tryptophan
,19594759,"absolute bioavailability, F(a),","In beagle dogs, the absorption of gaboxadol was almost complete (absolute bioavailability, F(a), of 85.3%) and T(max) was 0.46 h.",Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19594759/),%,85.3,4414,DB00150,L-Tryptophan
,19594759,T(max),"In beagle dogs, the absorption of gaboxadol was almost complete (absolute bioavailability, F(a), of 85.3%) and T(max) was 0.46 h.",Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19594759/),h,0.46,4415,DB00150,L-Tryptophan
,32325373,t1/2,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,3.51,8073,DB00150,L-Tryptophan
,32325373,t1/2,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,8.29,8074,DB00150,L-Tryptophan
,32325373,tmax,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,0.5 to 0.75,8075,DB00150,L-Tryptophan
,32325373,tmax,"GH levels increased after dosing, with a tmax of 0.75 h to 1.0 h.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,0.75,8076,DB00150,L-Tryptophan
,32325373,tmax,"GH levels increased after dosing, with a tmax of 0.75 h to 1.0 h.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,1.0,8077,DB00150,L-Tryptophan
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],31.9,8078,DB00150,L-Tryptophan
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],37.8,8079,DB00150,L-Tryptophan
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],18.4,8080,DB00150,L-Tryptophan
,31195673,IC50,Two compounds with a phenylimidazole scaffold (DX-03-12 and DX-03-13) showed potent IDO1 inhibition with IC50 values of 0.3-0.5 μM.,"Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195673/),μM,0.3-0.5,8376,DB00150,L-Tryptophan
,31195673,half-life,"The pharmacokinetic study revealed that DX-03-12 had satisfactory properties in mice, with rapid absorption, moderate plasma clearance (∼36% of hepatic blood flow), acceptable half-life (∼4.6 h), and high oral bioavailability (∼96%).","Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195673/),h,∼4.6,8377,DB00150,L-Tryptophan
,31195673,oral bioavailability,"The pharmacokinetic study revealed that DX-03-12 had satisfactory properties in mice, with rapid absorption, moderate plasma clearance (∼36% of hepatic blood flow), acceptable half-life (∼4.6 h), and high oral bioavailability (∼96%).","Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195673/),%,∼96,8378,DB00150,L-Tryptophan
,1835590,maximum tolerated dose,Myelosuppression was the dose-limiting toxicity and the maximum tolerated dose was 45 mg/m2.,"Phase I study of vintriptol, a tryptophan ester of vinblastine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835590/),[mg] / [m2],45,16566,DB00150,L-Tryptophan
,20100839,tissue half-life,"In vitro cell binding and in vivo tissue residence experiments demonstrate that aldehyde groups provide oxidized avidin the property to bind cellular and interstitial protein amino groups through Schiff's base formation, resulting in a tissue half-life of 2 weeks, compared with 2 h of native avidin.",Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20100839/),weeks,2,17939,DB00150,L-Tryptophan
,20100839,tissue half-life,"In vitro cell binding and in vivo tissue residence experiments demonstrate that aldehyde groups provide oxidized avidin the property to bind cellular and interstitial protein amino groups through Schiff's base formation, resulting in a tissue half-life of 2 weeks, compared with 2 h of native avidin.",Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20100839/),h,2,17940,DB00150,L-Tryptophan
,27266990,unbound area under the concentration curve,"After 23 μmol/kg i.p. bolus injection, the prodrugs' unbound area under the concentration curve in brain was 0.3 nmol/g × min, whereas the parent drugs could not reach the brain.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[nM] / [g·min],0.3,19802,DB00150,L-Tryptophan
,27266990,unbound brain concentrations,"The unbound brain concentrations of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[pM] / [g],521.4,19803,DB00150,L-Tryptophan
,27266990,unbound brain concentrations,"The unbound brain concentrations of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[pM] / [g],126.9,19804,DB00150,L-Tryptophan
,27266990,concentrations,"The combination of competing transporter substrates for LAT1, l-tryptophan, and for organic anion transporting polypeptides, probenecid, decreased the brain concentrations to 352.4 ± 44.5 and 70.9 ± 7.0 pmol/g, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),,35,19805,DB00150,L-Tryptophan
,18457023,absolute bioavailability,The absolute bioavailability of GB-115 is 4.65%.,Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18457023/),%,4.65,20969,DB00150,L-Tryptophan
,27990653,IC50,"A mechanistic population PD model was developed based on time-matched EPA, TRP, and KYN plasma concentrations in 44 oncology patients, and EPA in vivo IC50 was estimated to be ∼70 nM, consistent with the ex vivo value independently determined.",Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27990653/),nM,∼70,22633,DB00150,L-Tryptophan
,17868966,elimination t(1/2),"Thus, the doses were indicative of the lowest saturating doses in dogs and rats corresponding with an elimination t(1/2) of 6.0 h and 28.7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),h,6.0,22783,DB00150,L-Tryptophan
,17868966,elimination t(1/2),"Thus, the doses were indicative of the lowest saturating doses in dogs and rats corresponding with an elimination t(1/2) of 6.0 h and 28.7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),h,28.7,22784,DB00150,L-Tryptophan
,17868966,T(max),"Thus, the doses were indicative of the lowest saturating doses in dogs and rats corresponding with an elimination t(1/2) of 6.0 h and 28.7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),h,1,22785,DB00150,L-Tryptophan
,17868966,T(max),"Thus, the doses were indicative of the lowest saturating doses in dogs and rats corresponding with an elimination t(1/2) of 6.0 h and 28.7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),h,8,22786,DB00150,L-Tryptophan
,17868966,bioavailability,"Thus, the doses were indicative of the lowest saturating doses in dogs and rats corresponding with an elimination t(1/2) of 6.0 h and 28.7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),%,47,22787,DB00150,L-Tryptophan
,17868966,bioavailability,"Thus, the doses were indicative of the lowest saturating doses in dogs and rats corresponding with an elimination t(1/2) of 6.0 h and 28.7 h, a T(max) of 1h and 8h, and a bioavailability of 47% and 92%, respectively.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),%,92,22788,DB00150,L-Tryptophan
,17868966,plasma concentrations,"Mean plasma concentrations of D-1MT (600 and 1200 mg/m(2)/day) in dogs 1h post dosing were 54.4 and 69.5 microg/ml on Day 1, respectively, and 53.1 and 66.6 microg/ml on Day 28, respectively; thus, indicating no increase in plasma D-1MT with a change in dose.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),[μg] / [ml],54.4,22789,DB00150,L-Tryptophan
,17868966,plasma concentrations,"Mean plasma concentrations of D-1MT (600 and 1200 mg/m(2)/day) in dogs 1h post dosing were 54.4 and 69.5 microg/ml on Day 1, respectively, and 53.1 and 66.6 microg/ml on Day 28, respectively; thus, indicating no increase in plasma D-1MT with a change in dose.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),[μg] / [ml],69.5,22790,DB00150,L-Tryptophan
,17868966,plasma concentrations,"Mean plasma concentrations of D-1MT (600 and 1200 mg/m(2)/day) in dogs 1h post dosing were 54.4 and 69.5 microg/ml on Day 1, respectively, and 53.1 and 66.6 microg/ml on Day 28, respectively; thus, indicating no increase in plasma D-1MT with a change in dose.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),[μg] / [ml],53.1,22791,DB00150,L-Tryptophan
,17868966,plasma concentrations,"Mean plasma concentrations of D-1MT (600 and 1200 mg/m(2)/day) in dogs 1h post dosing were 54.4 and 69.5 microg/ml on Day 1, respectively, and 53.1 and 66.6 microg/ml on Day 28, respectively; thus, indicating no increase in plasma D-1MT with a change in dose.",Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17868966/),[μg] / [ml],66.6,22792,DB00150,L-Tryptophan
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],113.5,25323,DB00150,L-Tryptophan
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],94.2,25324,DB00150,L-Tryptophan
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],127.6,25325,DB00150,L-Tryptophan
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],85.2,25326,DB00150,L-Tryptophan
,26653033,oral bioavailability,"Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide 40, which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body weight loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.","Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26653033/),%,59,34104,DB00150,L-Tryptophan
,6187038,biological half-life,"The biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearance ranged from 0.10 to 0.23 1/kg/hour.",Kinetics of l-5-hydroxytryptophan in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6187038/),h,2.2 to 7.4,35579,DB00150,L-Tryptophan
,6187038,plasma clearance,"The biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearance ranged from 0.10 to 0.23 1/kg/hour.",Kinetics of l-5-hydroxytryptophan in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6187038/),[1] / [h·kg],0.10 to 0.23,35580,DB00150,L-Tryptophan
,6187038,bioavailability,The bioavailability of 5-HTP after oral administration in combination with carbidopa was calculated as 48% +/- 15 (mean +/- SD).,Kinetics of l-5-hydroxytryptophan in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6187038/),%,48,35581,DB00150,L-Tryptophan
,9193870,AUC,"Doses (iv) of the compound showed high plasma levels, resulting in AUC values of 30-33 micrograms-hr/ml for mice and dogs after 20 and 7.5 mg/kg doses, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),[μgrams-hr] / [ml],30-33,35734,DB00150,L-Tryptophan
,9193870,Half-life,"Half-life values for mice and dogs were about 7 and 2 hr, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),h,7,35735,DB00150,L-Tryptophan
,9193870,Half-life,"Half-life values for mice and dogs were about 7 and 2 hr, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),h,2,35736,DB00150,L-Tryptophan
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,56,35737,DB00150,L-Tryptophan
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,46,35738,DB00150,L-Tryptophan
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,81,35739,DB00150,L-Tryptophan
,26525153,time to maximal plasma concentration (tmax,"In this group, time to maximal plasma concentration (tmax , mean ± S.D.) was 37.5 ± 15 min., terminal plasma half-life was approximately 3.7 h (60% CI: 2.1-15.6 h), maximal plasma concentration (Cmax) was 61.3 ± 7.6 μM, and AUC was 200 ± 54 μmol·h/l.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),min,37.5,38411,DB00150,L-Tryptophan
,26525153,terminal plasma half-life,"In this group, time to maximal plasma concentration (tmax , mean ± S.D.) was 37.5 ± 15 min., terminal plasma half-life was approximately 3.7 h (60% CI: 2.1-15.6 h), maximal plasma concentration (Cmax) was 61.3 ± 7.6 μM, and AUC was 200 ± 54 μmol·h/l.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),h,3.7,38412,DB00150,L-Tryptophan
,26525153,maximal plasma concentration (Cmax),"In this group, time to maximal plasma concentration (tmax , mean ± S.D.) was 37.5 ± 15 min., terminal plasma half-life was approximately 3.7 h (60% CI: 2.1-15.6 h), maximal plasma concentration (Cmax) was 61.3 ± 7.6 μM, and AUC was 200 ± 54 μmol·h/l.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),μM,61.3,38413,DB00150,L-Tryptophan
,26525153,AUC,"In this group, time to maximal plasma concentration (tmax , mean ± S.D.) was 37.5 ± 15 min., terminal plasma half-life was approximately 3.7 h (60% CI: 2.1-15.6 h), maximal plasma concentration (Cmax) was 61.3 ± 7.6 μM, and AUC was 200 ± 54 μmol·h/l.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),[h·μM] / [l],200,38414,DB00150,L-Tryptophan
,26525153,Maximal tissue levels (Cmax,"Maximal tissue levels (Cmax in μmol/kg) were 6.9 ± 6.7, 1.6 ± 0.4 and 3.4 ± 1.1 in liver, skeletal and heart muscle, respectively.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),μ,6.9,38415,DB00150,L-Tryptophan
,26525153,Maximal tissue levels (Cmax,"Maximal tissue levels (Cmax in μmol/kg) were 6.9 ± 6.7, 1.6 ± 0.4 and 3.4 ± 1.1 in liver, skeletal and heart muscle, respectively.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),μ,1.6,38416,DB00150,L-Tryptophan
,26525153,Maximal tissue levels (Cmax,"Maximal tissue levels (Cmax in μmol/kg) were 6.9 ± 6.7, 1.6 ± 0.4 and 3.4 ± 1.1 in liver, skeletal and heart muscle, respectively.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),μ,3.4,38417,DB00150,L-Tryptophan
,26525153,50% inhibitory concentration,"We conclude that despite its high lipophilicity, RG 108 can be used for in vivo experiments, appears safe and yields plasma and tissue levels in the range of the described 50% inhibitory concentration of around 1 to 5 μM.",Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor N-Phthalyl-L-Tryptophan (RG 108) in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525153/),μM,1 to 5,38418,DB00150,L-Tryptophan
,22577815,absorption fraction,"The absorption fraction of gaboxadol was high (81.3-91.3%) following its administration into the stomach, duodenum and jejunum, but low (4.2%) after administration into the colon.",Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22577815/),%,81.3-91.3,40726,DB00150,L-Tryptophan
,22577815,absorption fraction,"The absorption fraction of gaboxadol was high (81.3-91.3%) following its administration into the stomach, duodenum and jejunum, but low (4.2%) after administration into the colon.",Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22577815/),%,4.2,40727,DB00150,L-Tryptophan
,29111717,half-life,"Clinical candidate 6 shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.","Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29111717/),h,16-19,62746,DB00150,L-Tryptophan
,30927450,run times,"Here we present the validation of the method for the quantitation of mithramycin SA-tryptophan (MTMSA-Trp) as well as the applicability of the methodology for assaying additional analogs, including MTM, mithramycin SK (MTMSK) and mithramycin SA-phenylalanine (MTMSA-Phe) with run times of 6 min.",Bioanalytical method for quantitative determination of mithramycin analogs in mouse plasma by HPLC-QTOF. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30927450/),min,6,65110,DB00150,L-Tryptophan
,33682377,plasma,"After infusion, LKYN plasma concentration increased significantly over time 3.23 ± 1.12 µg/mL (after 50 µg/kg), 4.04 ± 1.1 µg/mL (after 100 µg/kg), and 5.25 ± 1.01 µg/mL (after 150 µg/kg) (p ≤ 0.001).","Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33682377/),[μg] / [ml],3.23,66508,DB00150,L-Tryptophan
,33682377,plasma,"After infusion, LKYN plasma concentration increased significantly over time 3.23 ± 1.12 µg/mL (after 50 µg/kg), 4.04 ± 1.1 µg/mL (after 100 µg/kg), and 5.25 ± 1.01 µg/mL (after 150 µg/kg) (p ≤ 0.001).","Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33682377/),[μg] / [ml],4.04,66509,DB00150,L-Tryptophan
,33682377,plasma,"After infusion, LKYN plasma concentration increased significantly over time 3.23 ± 1.12 µg/mL (after 50 µg/kg), 4.04 ± 1.1 µg/mL (after 100 µg/kg), and 5.25 ± 1.01 µg/mL (after 150 µg/kg) (p ≤ 0.001).","Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33682377/),[μg] / [ml],5.25,66510,DB00150,L-Tryptophan
,6650965,Net absorption,"Net absorption of 3MI and indole peaked at an average of 1.05 and 0.81 g/hr, respectively.",Net absorption of 3-methylindole and indole in cattle after oral administration of L-tryptophan. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650965/),[g] / [h],1.05,68918,DB00150,L-Tryptophan
,6650965,Net absorption,"Net absorption of 3MI and indole peaked at an average of 1.05 and 0.81 g/hr, respectively.",Net absorption of 3-methylindole and indole in cattle after oral administration of L-tryptophan. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650965/),[g] / [h],0.81,68919,DB00150,L-Tryptophan
,32422549,oral bioavailability,"Two prodrugs that produced the highest exposure to indoximod in rats were further tested in Cynomolgus monkeys, a species in which indoximod has oral bioavailability of 6-10% and an equivalent dose-dependent exposure profile as humans.",Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422549/),%,6-10,72856,DB00150,L-Tryptophan
,20477958,rate constant,"The HPLC analysis revealed almost complete disappearance of butachlor within 20 days in soil at a rate constant of 0.17 day(-1) and half-life (t((1/2))) of 4.0 days, following the first-order rate kinetics.",Isolation and characterization of butachlor-catabolizing bacterial strain Stenotrophomonas acidaminiphila JS-1 from soil and assessment of its biodegradation potential. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20477958/),1/[day],0.17,74845,DB00150,L-Tryptophan
,20477958,half-life (t((1/2))),"The HPLC analysis revealed almost complete disappearance of butachlor within 20 days in soil at a rate constant of 0.17 day(-1) and half-life (t((1/2))) of 4.0 days, following the first-order rate kinetics.",Isolation and characterization of butachlor-catabolizing bacterial strain Stenotrophomonas acidaminiphila JS-1 from soil and assessment of its biodegradation potential. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20477958/),d,4.0,74846,DB00150,L-Tryptophan
,3747417,transfer,The tryptophan transfer in cirrhosis amounted to only 0.75 +/- 0.03 g per 24 h compared with 2.6 +/- 0.34 g per 24 h in healthy individuals.,[Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3747417/),[g] / [24·h],0.75,78338,DB00150,L-Tryptophan
,3747417,transfer,The tryptophan transfer in cirrhosis amounted to only 0.75 +/- 0.03 g per 24 h compared with 2.6 +/- 0.34 g per 24 h in healthy individuals.,[Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3747417/),[g] / [24·h],2.6,78339,DB00150,L-Tryptophan
,17386754,separation factor,"Under this condition, the separation factor and resolution were 1.48 and 1.28, respectively.",Development of a column-switching high-performance liquid chromatography for kynurenine enantiomers and its application to a pharmacokinetic study in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386754/),,1.48,83187,DB00150,L-Tryptophan
,17386754,resolution,"Under this condition, the separation factor and resolution were 1.48 and 1.28, respectively.",Development of a column-switching high-performance liquid chromatography for kynurenine enantiomers and its application to a pharmacokinetic study in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386754/),,1,83188,DB00150,L-Tryptophan
,11811421,association equilibrium constant (Ka),"The association equilibrium constant (Ka) and the association and dissociation rate constants (k(a) and k(d), respectively) were thereby measured in an aqueous pH 7.4 environment at 37 degrees C as 0.84 10(4) M(-1), 5.8 10(4) M(-1) s(-1), and 6.9 s(-1), respectively.",Determination of drug-plasma protein binding kinetics and equilibria by chromatographic profiling: exemplification of the method using L-tryptophan and albumin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11811421/),1/[M],0.84,83847,DB00150,L-Tryptophan
,11811421,k(d),"The association equilibrium constant (Ka) and the association and dissociation rate constants (k(a) and k(d), respectively) were thereby measured in an aqueous pH 7.4 environment at 37 degrees C as 0.84 10(4) M(-1), 5.8 10(4) M(-1) s(-1), and 6.9 s(-1), respectively.",Determination of drug-plasma protein binding kinetics and equilibria by chromatographic profiling: exemplification of the method using L-tryptophan and albumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11811421/),1/[s],6.9,83848,DB00150,L-Tryptophan
,29921320,Tmax,"Navoximod was rapidly absorbed (Tmax ~ 1 h) and exhibited dose-proportional increases in exposure, with a half-life (t1/2 ~ 11 h) supportive of BID dosing.","Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29921320/),h,1,84599,DB00150,L-Tryptophan
,29921320,half-life (t1/2,"Navoximod was rapidly absorbed (Tmax ~ 1 h) and exhibited dose-proportional increases in exposure, with a half-life (t1/2 ~ 11 h) supportive of BID dosing.","Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29921320/),h,11,84600,DB00150,L-Tryptophan
,22234618,absolute bioavailability,Increasing the dose of vigabatrin 10-fold decreased the absolute bioavailability to 4.2%.,"Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22234618/),%,4.2,84796,DB00150,L-Tryptophan
,22234618,K(m),Laevis oocytes had a K(m) of 5.2 ± 0.6 mM and was almost completely inhibited by tryptophan.,"Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22234618/),mM,5.2,84797,DB00150,L-Tryptophan
,19293342,area under the curve for 0 to 24 hours,Results are given as mean +/- SEM: The area under the curve for 0 to 24 hours is approximately twice as high without food (27.8 +/- 4.1) than with food (13.7 +/- 1.2; P = .002).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),,27.8,85728,DB00150,L-Tryptophan
,19293342,area under the curve for 0 to 24 hours,Results are given as mean +/- SEM: The area under the curve for 0 to 24 hours is approximately twice as high without food (27.8 +/- 4.1) than with food (13.7 +/- 1.2; P = .002).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),,13.7,85729,DB00150,L-Tryptophan
,19293342,maximum observed ARD-07 concentration relative to dose administration (C(max)),The maximum observed ARD-07 concentration relative to dose administration (C(max)) is more than twice as high without food (10.6 +/- 1.6 ng/mL) than with food (4.4 +/- 0.5 ng/mL; P = .001).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],10.6,85730,DB00150,L-Tryptophan
,19293342,maximum observed ARD-07 concentration relative to dose administration (C(max)),The maximum observed ARD-07 concentration relative to dose administration (C(max)) is more than twice as high without food (10.6 +/- 1.6 ng/mL) than with food (4.4 +/- 0.5 ng/mL; P = .001).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],4.4,85731,DB00150,L-Tryptophan
,19293342,C(max),C(max) of growth hormone occurs at a significantly (P = .001) later stage with food (C(max) = 13.0 +/- 3.5 ng/mL) than without food (37.1 +/- 5.3 ng/mL).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],13.0,85732,DB00150,L-Tryptophan
,19293342,C(max),C(max) of growth hormone occurs at a significantly (P = .001) later stage with food (C(max) = 13.0 +/- 3.5 ng/mL) than without food (37.1 +/- 5.3 ng/mL).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],37.1,85733,DB00150,L-Tryptophan
,4018078,plasma clearance,"However, its plasma clearance was significantly higher in NAR (45.7 ml kg-1 min-1) than in normal rats (25.2 ml kg-1 min-1).",Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],45.7,106839,DB00150,L-Tryptophan
,4018078,plasma clearance,"However, its plasma clearance was significantly higher in NAR (45.7 ml kg-1 min-1) than in normal rats (25.2 ml kg-1 min-1).",Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],25.2,106840,DB00150,L-Tryptophan
,4018078,association constant,The mercapturic acid bound to plasma albumin with an association constant of 2.24 X 10(5) M-1 and the number of binding sites was 1.18/mol albumin.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),1/[M],2.24 X 10(5),106841,DB00150,L-Tryptophan
,4018078,number of binding sites,The mercapturic acid bound to plasma albumin with an association constant of 2.24 X 10(5) M-1 and the number of binding sites was 1.18/mol albumin.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),1/[mol],1.18,106842,DB00150,L-Tryptophan
,4018078,plasma clearance,Concomitant administration of this mercapturic acid with equimolar amounts of albumin resulted in a marked decrease in the plasma clearance (26.2 ml kg-1 min-1) and an increase in the urinary secretion of this ligand in NAR.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],26.2,106843,DB00150,L-Tryptophan
,34110158,IC50,"Crystal structure-guided optimization led to 23, which manifested IC50 values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.","X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34110158/),μM,0.64,127676,DB00150,L-Tryptophan
,34110158,IC50,"Crystal structure-guided optimization led to 23, which manifested IC50 values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.","X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34110158/),μM,0.04,127677,DB00150,L-Tryptophan
,25562534,Michaelis constant,"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),mM,32.8,128187,DB00150,L-Tryptophan
,25562534,maximal oral absorption rate (Vmax),"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),[mM] / [min],64.6,128188,DB00150,L-Tryptophan
,25562534,bioavailability,"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,60.9,128189,DB00150,L-Tryptophan
,25562534,Bioavailability,"Bioavailability was 58.5-60.8% at 0.3-30mg/kg doses, but decreased to 46.8% at 300mg/kg.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,58.5-60.8,128190,DB00150,L-Tryptophan
,25562534,Bioavailability,"Bioavailability was 58.5-60.8% at 0.3-30mg/kg doses, but decreased to 46.8% at 300mg/kg.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,46.8,128191,DB00150,L-Tryptophan
,311987,apparent composite 1. order rate constants alpha,"The apparent composite 1. order rate constants alpha and beta were 1.433 hr-1 +/- 0.177 S.D. and 0.113 hr-1 +/- 0.012 hr-1 S.D., respectively.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),1/[h],1.433,133074,DB00150,L-Tryptophan
,311987,beta,"The apparent composite 1. order rate constants alpha and beta were 1.433 hr-1 +/- 0.177 S.D. and 0.113 hr-1 +/- 0.012 hr-1 S.D., respectively.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),1/[h],0.113,133075,DB00150,L-Tryptophan
,311987,biological half-life,The biological half-life of 5-hydroxytryptophan under the experimental conditions was thus about 6 hours.,Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),h,6,133076,DB00150,L-Tryptophan
,311987,"apparent volume of the central compartment, Vc","The apparent volume of the central compartment, Vc, was found to be 0.336 1 kg-1 +/- 0.059 S.D. and the plasma clearance 0.105 1 hr-1 kg-1 +/- 0.015 S.D.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),[1] / [kg],0.336,133077,DB00150,L-Tryptophan
,311987,plasma clearance,"The apparent volume of the central compartment, Vc, was found to be 0.336 1 kg-1 +/- 0.059 S.D. and the plasma clearance 0.105 1 hr-1 kg-1 +/- 0.015 S.D.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),[1] / [h·kg],0.105,133078,DB00150,L-Tryptophan
,19878101,half-life,N-acetyl-DL-tryptophan had a half-life of approximately 30 min.,Infusions of albumin increase free fraction of naproxen in healthy volunteers: a randomized crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878101/),min,30,133085,DB00150,L-Tryptophan
<,19878101,half-life,The half-life of caprylate was <15 min.,Infusions of albumin increase free fraction of naproxen in healthy volunteers: a randomized crossover study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878101/),min,15,133086,DB00150,L-Tryptophan
,31981851,half-life,The half-life of epacadostat is 2.4 h in human and dosage is 50 mg BID in the phase III clinic trial.,"Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),h,2.4,134421,DB00150,L-Tryptophan
,31981851,IC50,"Among them, compound 23, 25 and 26 showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM respectively) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM respectively).","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),nM,108.7,134422,DB00150,L-Tryptophan
,31981851,IC50,"Among them, compound 23, 25 and 26 showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM respectively) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM respectively).","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),nM,178.1,134423,DB00150,L-Tryptophan
,31981851,IC50,"Among them, compound 23, 25 and 26 showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM respectively) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM respectively).","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),nM,139.1,134424,DB00150,L-Tryptophan
,31981851,IC50,"Among them, compound 23, 25 and 26 showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM respectively) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM respectively).","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),nM,19.88,134425,DB00150,L-Tryptophan
,31981851,IC50,"Among them, compound 23, 25 and 26 showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM respectively) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM respectively).","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),nM,68.59,134426,DB00150,L-Tryptophan
,31981851,IC50,"Among them, compound 23, 25 and 26 showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM respectively) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM respectively).","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),nM,57.76,134427,DB00150,L-Tryptophan
,31981851,half-life (t1/2,"Moreover, compound 25 displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),h,3.81,134428,DB00150,L-Tryptophan
,31981851,oral bioavailability (F,"Moreover, compound 25 displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.","Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981851/),%,33.6,134429,DB00150,L-Tryptophan
,2298826,half-life,The half-life of the precursor pool is estimated to be approximately 20 min.,A new method to measure brain serotonin synthesis in vivo. I. Theory and basic data for a biological model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298826/),min,20,135532,DB00150,L-Tryptophan
,6527280,urine excretion,The specificity of I was higher as indicated by 94% in the bile at 90 min compared to 91% for II in normal rats and a urine excretion of 0.3% for I compared with 1.9% for II.,"Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),%,0.3,138284,DB00150,L-Tryptophan
,6527280,urine excretion,The specificity of I was higher as indicated by 94% in the bile at 90 min compared to 91% for II in normal rats and a urine excretion of 0.3% for I compared with 1.9% for II.,"Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),%,1.9,138285,DB00150,L-Tryptophan
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],70,138286,DB00150,L-Tryptophan
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],47,138287,DB00150,L-Tryptophan
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],51,138288,DB00150,L-Tryptophan
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],30,138289,DB00150,L-Tryptophan
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],10,143199,DB00150,L-Tryptophan
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],3.5,143200,DB00150,L-Tryptophan
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],29,143201,DB00150,L-Tryptophan
,12369274,stabilized concentrations,"The therapeutic drug monitoring needed oral Risp daily dose of 4.5 +/- 2.3 mg (range 2-8) and the stabilized concentrations (ng/ml) at endpoint in plasma and RBC were 10 +/- 8 (range 1-23) and 3.5 +/- 2 (range 1-8) for Risp and 29 +/- 19 (range 8-70) and 11.5 +/- 6.6 (range 2.6-22.5) for 9-OH-Risp, respectively.","Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369274/),[ng] / [ml],11.5,143202,DB00150,L-Tryptophan
,9438020,binding affinities,"This SAR study led to the identification of tricyclo[3.3.1.1(3,7)]dec-2-yl [1S-[1 alpha(S*)2 beta]-[2-[(2-hydroxycyclohexyl)amino]-1-(1H-indol-3- ylmethyl)-1-methyl-2-oxoethyl]carbamate (CI-1015, 31) with binding affinities of 3.0 and 2900 nM for the CCK-B and CCK-A receptors, respectively.","Second generation ""peptoid"" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438020/),nM,3.0,144638,DB00150,L-Tryptophan
,9438020,binding affinities,"This SAR study led to the identification of tricyclo[3.3.1.1(3,7)]dec-2-yl [1S-[1 alpha(S*)2 beta]-[2-[(2-hydroxycyclohexyl)amino]-1-(1H-indol-3- ylmethyl)-1-methyl-2-oxoethyl]carbamate (CI-1015, 31) with binding affinities of 3.0 and 2900 nM for the CCK-B and CCK-A receptors, respectively.","Second generation ""peptoid"" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438020/),nM,2900,144639,DB00150,L-Tryptophan
,9438020,Ke,The compound showed CCK-B antagonist profile in the rat ventromedial hypothalamus assay with a Ke of 34 nM.,"Second generation ""peptoid"" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438020/),nM,34,144640,DB00150,L-Tryptophan
,9438020,minimum effective dose (MED),It also showed an anxiolytic like profile orally in a standard anxiety paradigm (X-maze) with a minimum effective dose (MED) of 0.1 microgram/kg.,"Second generation ""peptoid"" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438020/),[μg] / [kg],0.1,144641,DB00150,L-Tryptophan
,24561703,IC50,The IC50 value of LisW-S was 38.5 nM in rat plasma using the fluorogenic substrate Abz-FRKP(Dnp)P-OH.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),nM,38.5,145586,DB00150,L-Tryptophan
,24561703,Cmax,The Cmax obtained following oral administration of the drug was 0.082 μM and LisW-S had an apparent terminal elimination half-life of around 3.1 h.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),μM,0.082,145587,DB00150,L-Tryptophan
,24561703,apparent terminal elimination half-life,The Cmax obtained following oral administration of the drug was 0.082 μM and LisW-S had an apparent terminal elimination half-life of around 3.1 h.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),h,3.1,145588,DB00150,L-Tryptophan
,24561703,oral bioavailability,The pharmacokinetic data indicate that the oral bioavailability of LisW-S was approximately 5.4%.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),%,5.4,145589,DB00150,L-Tryptophan
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],2.69,154767,DB00150,L-Tryptophan
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],2.58,154768,DB00150,L-Tryptophan
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],0.82,154769,DB00150,L-Tryptophan
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],0.34,154770,DB00150,L-Tryptophan
,133325,renal clearance,"However, the average renal clearance of tryptophan during the first 6 hr of the loading tests in the patient was 0.757 ml plasma/1.73 m2 and that in the control subjects was 0.706 ml plasma/1.73 m2.",A defect in tryptophan metabolism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[ml·plasma] / [1.73·m2],0.757,154771,DB00150,L-Tryptophan
,133325,renal clearance,"However, the average renal clearance of tryptophan during the first 6 hr of the loading tests in the patient was 0.757 ml plasma/1.73 m2 and that in the control subjects was 0.706 ml plasma/1.73 m2.",A defect in tryptophan metabolism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[ml·plasma] / [1.73·m2],0.706,154772,DB00150,L-Tryptophan
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,7,161535,DB00150,L-Tryptophan
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,14,161536,DB00150,L-Tryptophan
,18719048,C(max),"Compared with 5-HTP/CBD/placebo, granisetron addition decreased C(max) of 5-HTP statistically significantly different (from 1483 to 1272 ng/ml) without influencing AUC(0- infinity).",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),[ng] / [ml],1483,161537,DB00150,L-Tryptophan
,32961034,ΔΔ,"The ΔΔQTcF for macimorelin showed a prolongation with a maximum mean value of 9.61 milliseconds (2-sided 90% confidence interval, 7.81 milliseconds and 11.41 milliseconds) at 4 hours after dosing.",Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32961034/),,9.61,176536,DB00150,L-Tryptophan
,10611459,initial plasma half life,Administration of [14C]NCR-631 suggested 20 min initial plasma half life and an oral absorption around 50%.,"3-Hydroxyanthranilic acid accumulation following administration of the 3-hydroxyanthranilic acid 3,4-dioxygenase inhibitor NCR-631. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611459/),min,20,183374,DB00150,L-Tryptophan
,10611459,oral absorption,Administration of [14C]NCR-631 suggested 20 min initial plasma half life and an oral absorption around 50%.,"3-Hydroxyanthranilic acid accumulation following administration of the 3-hydroxyanthranilic acid 3,4-dioxygenase inhibitor NCR-631. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611459/),%,50,183375,DB00150,L-Tryptophan
,6966118,systemic availability,"The systemic availability of L-5-hydroxytryptophan exhibited an interindividual range of 47-84%, with a mean value of 69.2% +/- 4.7 S.E.M.",Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966118/),%,47-84,192852,DB00150,L-Tryptophan
,6966118,systemic availability,"The systemic availability of L-5-hydroxytryptophan exhibited an interindividual range of 47-84%, with a mean value of 69.2% +/- 4.7 S.E.M.",Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966118/),%,69.2,192853,DB00150,L-Tryptophan
,32210078,IC50,"Among them, the three phenyl urea derivatives i12, i23, i24 as showed potent IDO1 inhibition, with IC50 values of 0.1-0.6 μM and no compound exhibited TDO inhibitory activity.","Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32210078/),μM,0.1-0.6,195538,DB00150,L-Tryptophan
,32210078,plasma clearance,"The pharmacokinetic study revealed that compound i12 had satisfactory properties in mice, with moderate plasma clearance (22.45 mL/min/kg), acceptable half-life (11.2 h) and high oral bioavailability (87.4%).","Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32210078/),[ml] / [kg·min],22.45,195539,DB00150,L-Tryptophan
,32210078,half-life,"The pharmacokinetic study revealed that compound i12 had satisfactory properties in mice, with moderate plasma clearance (22.45 mL/min/kg), acceptable half-life (11.2 h) and high oral bioavailability (87.4%).","Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32210078/),h,11.2,195540,DB00150,L-Tryptophan
,32210078,oral bioavailability,"The pharmacokinetic study revealed that compound i12 had satisfactory properties in mice, with moderate plasma clearance (22.45 mL/min/kg), acceptable half-life (11.2 h) and high oral bioavailability (87.4%).","Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32210078/),%,87.4,195541,DB00150,L-Tryptophan
,22942319,areas under the concentration-time curves (AUCs) from 0 to infinity,"After a 0.05 mg/kg Ro-61-8048 oral dose alone or coadministered with 10 mg/kg JM6 to mice, the Ro-61-8048 areas under the concentration-time curves (AUCs) from 0 to infinity were similar (4300 and 4900 nM × h, respectively), indicating no detectable contributions of JM6 metabolism to the Ro-61-8048 AUCs.",Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22942319/),h·nM,4300,197779,DB00150,L-Tryptophan
,22942319,areas under the concentration-time curves (AUCs) from 0 to infinity,"After a 0.05 mg/kg Ro-61-8048 oral dose alone or coadministered with 10 mg/kg JM6 to mice, the Ro-61-8048 areas under the concentration-time curves (AUCs) from 0 to infinity were similar (4300 and 4900 nM × h, respectively), indicating no detectable contributions of JM6 metabolism to the Ro-61-8048 AUCs.",Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22942319/),h·nM,4900,197780,DB00150,L-Tryptophan
,10460206,bioavailabilities,"Tryptophan bioavailabilities of various formulas varied from 83 to 95%, with some of the liquid concentrates having the lowest values.","Liquid concentrates are lower in bioavailable tryptophan than powdered infant formulas, and tryptophan supplementation of formulas increases brain tryptophan and serotonin in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460206/),%,83 to 95,198881,DB00150,L-Tryptophan
,10460206,bioavailable,The levels of bioavailable tryptophan in the liquid concentrate forms (9.7-12.6 mg/g protein) and the powdered forms (11.1-13.1 mg/g protein) were considerably lower than those of human milk (17-19 mg/g protein).,"Liquid concentrates are lower in bioavailable tryptophan than powdered infant formulas, and tryptophan supplementation of formulas increases brain tryptophan and serotonin in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460206/),[mg] / [g],9.7-12.6,198882,DB00150,L-Tryptophan
,10460206,bioavailable,The levels of bioavailable tryptophan in the liquid concentrate forms (9.7-12.6 mg/g protein) and the powdered forms (11.1-13.1 mg/g protein) were considerably lower than those of human milk (17-19 mg/g protein).,"Liquid concentrates are lower in bioavailable tryptophan than powdered infant formulas, and tryptophan supplementation of formulas increases brain tryptophan and serotonin in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460206/),[mg] / [g],11.1-13.1,198883,DB00150,L-Tryptophan
,10460206,bioavailable,The levels of bioavailable tryptophan in the liquid concentrate forms (9.7-12.6 mg/g protein) and the powdered forms (11.1-13.1 mg/g protein) were considerably lower than those of human milk (17-19 mg/g protein).,"Liquid concentrates are lower in bioavailable tryptophan than powdered infant formulas, and tryptophan supplementation of formulas increases brain tryptophan and serotonin in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460206/),[mg] / [g],17-19,198884,DB00150,L-Tryptophan
,33882449,half-life,The half-life of 5-HTP was dose-independent (128 min).,Residual effects of abomasal 5-hydroxytryptophan administration on serotonin metabolism in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33882449/),min,128,201954,DB00150,L-Tryptophan
>,8904710,bioavailability,"For each of the three dependent variables, estimates of tryptophan bioavailability were > 100% when daily supplemental tryptophan intake was used as the independent variable.",Bioavailability of tryptophan in soybean meal for 10-kg pigs using slope-ratio assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904710/),%,100,207134,DB00150,L-Tryptophan
,8904710,bioavailability,"Estimates of TRP bioavailability based on nonpartitioned ADG were 90, 99, and 110% when supplemental TRP level, daily total TRP intake, and daily supplemental TRP intake were used as the independent variables, respectively.",Bioavailability of tryptophan in soybean meal for 10-kg pigs using slope-ratio assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904710/),%,90,207135,DB00150,L-Tryptophan
,8904710,bioavailability,"Estimates of TRP bioavailability based on nonpartitioned ADG were 90, 99, and 110% when supplemental TRP level, daily total TRP intake, and daily supplemental TRP intake were used as the independent variables, respectively.",Bioavailability of tryptophan in soybean meal for 10-kg pigs using slope-ratio assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904710/),%,99,207136,DB00150,L-Tryptophan
,8904710,bioavailability,"Estimates of TRP bioavailability based on nonpartitioned ADG were 90, 99, and 110% when supplemental TRP level, daily total TRP intake, and daily supplemental TRP intake were used as the independent variables, respectively.",Bioavailability of tryptophan in soybean meal for 10-kg pigs using slope-ratio assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904710/),%,110,207137,DB00150,L-Tryptophan
,12669967,Renal excretion,"Renal excretion of unchanged prodrug (16.4 +/- 5.6% of the total dose administered intravenously), its conversion to AZT (12.1 +/- 5.4% of total dose administered intravenously), and its biliary excretion (54.3 +/- 4.9% of the total dose up to 4 h after intravenous administration) accounted for most of the elimination of NMe-Trp-AZT.",Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12669967/),%,16.4,207165,DB00150,L-Tryptophan
,12669967,biliary excretion,"Renal excretion of unchanged prodrug (16.4 +/- 5.6% of the total dose administered intravenously), its conversion to AZT (12.1 +/- 5.4% of total dose administered intravenously), and its biliary excretion (54.3 +/- 4.9% of the total dose up to 4 h after intravenous administration) accounted for most of the elimination of NMe-Trp-AZT.",Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12669967/),%,54.3,207166,DB00150,L-Tryptophan
,8194283,elimination half-life,"The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days.",Clinical pharmacokinetics of fluoxetine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194283/),d,1 to 4,219943,DB00150,L-Tryptophan
,8194283,elimination half-life,"The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days.",Clinical pharmacokinetics of fluoxetine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194283/),d,7 to 15,219944,DB00150,L-Tryptophan
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],172.0,224639,DB00150,L-Tryptophan
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],258.3,224640,DB00150,L-Tryptophan
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],328.47,224641,DB00150,L-Tryptophan
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],387.3,224642,DB00150,L-Tryptophan
,18308795,oral clearance,5-HTP kinetics were adequately described using a one-compartment model with first-order absorption and a lag time (mean oral clearance 28 L/h interindividual coefficient of variation 31%).,Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[l] / [h],28,224643,DB00150,L-Tryptophan
,33316404,IC50,"Representative compound 18 inhibited human IDO1 with IC50 values of 3.9 nM and 52 nM in a cellular and human whole blood assay, respectively.",Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316404/),nM,3.9,232833,DB00150,L-Tryptophan
,33316404,IC50,"Representative compound 18 inhibited human IDO1 with IC50 values of 3.9 nM and 52 nM in a cellular and human whole blood assay, respectively.",Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316404/),nM,52,232834,DB00150,L-Tryptophan
,34327739,apparent volume of distribution,"GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr.","Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327739/),l,20.6,235610,DB00150,L-Tryptophan
,34327739,apparent volume of distribution,"GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr.","Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327739/),l,44.6,235611,DB00150,L-Tryptophan
,34327739,clearance,"GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr.","Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327739/),[l] / [h],0.462,235612,DB00150,L-Tryptophan
,34327739,clearance,"GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr.","Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327739/),[l] / [h],0.805,235613,DB00150,L-Tryptophan
,34327739,terminal half-life,"GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr.","Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327739/),h,31.3 and 34.5,235614,DB00150,L-Tryptophan
,6802644,Peak serum tryptophan levels,Peak serum tryptophan levels (911-1002 mumol/l) occurred 2 h after the load.,Effects of age on serum tryptophan and urine indican in adults given a tryptophan load test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6802644/),[μM] / [l],911-1002,241467,DB00150,L-Tryptophan
,6802644,excretion,Urinary indican excretion on the day of the load averaged 6.4 mumol/24h/kg of body weight (+/- 2.8 s.d.).,Effects of age on serum tryptophan and urine indican in adults given a tryptophan load test. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6802644/),[μM] / [24h·kg],6.4,241468,DB00150,L-Tryptophan
,6190484,biological half-life,"The intracerebral level of morphine was found to depend on the dose injected, and the biological half-life of the drug was estimated to be about 1 hr.",Direct correlation between level of morphine and its biochemical effect on monoamine systems in mouse brain. Evidence for involvement of dopaminergic neurons in the pharmacological action of acute morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6190484/),h,1,248070,DB00150,L-Tryptophan
,19900542,K(m),Gaboxadol was a substrate for the renal transporter rOat1 with a K(m)-value of 151 microM.,5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19900542/),μM,151,254300,DB00150,L-Tryptophan
,27008709,Cmax,"Cmax (~12 μM at 2000 mg twice/day) occurred at 2.9 hours, and half-life was 10.5 hours.",A phase I study of indoximod in patients with advanced malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008709/),μM,12,257439,DB00150,L-Tryptophan
,27008709,half-life,"Cmax (~12 μM at 2000 mg twice/day) occurred at 2.9 hours, and half-life was 10.5 hours.",A phase I study of indoximod in patients with advanced malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008709/),h,10.5,257440,DB00150,L-Tryptophan
,26552594,specific activity,"(11)C-L-1MTrp and (11)C-D-1MTrp were synthesized rapidly with radiochemical yields of 47 ± 6.3% (decay-corrected, based on (11)C-CO2), a radiochemical purity of >98%, specific activity of 47-130 GBq/μmol, and high enantiomeric purity.",Development of 1-N-(11)C-Methyl-L- and -D-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26552594/),[gbq] / [μM],47-130,270462,DB00150,L-Tryptophan
>,12439293,availability,"The availability of unchanged tracer in arterial blood plasma was > or = 80% up to 60 minutes after injection, while [11C]-hydroxyindole acetic acid and [11C]-serotonin accounted for the remaining radioactivity, amounting to < or = 16% and < or = 4%, respectively.",Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439293/),%,80,273178,DB00150,L-Tryptophan
<,12439293,availability,"The availability of unchanged tracer in arterial blood plasma was > or = 80% up to 60 minutes after injection, while [11C]-hydroxyindole acetic acid and [11C]-serotonin accounted for the remaining radioactivity, amounting to < or = 16% and < or = 4%, respectively.",Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439293/),%,16,273179,DB00150,L-Tryptophan
<,12439293,availability,"The availability of unchanged tracer in arterial blood plasma was > or = 80% up to 60 minutes after injection, while [11C]-hydroxyindole acetic acid and [11C]-serotonin accounted for the remaining radioactivity, amounting to < or = 16% and < or = 4%, respectively.",Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439293/),%,4,273180,DB00150,L-Tryptophan
,12439293,biologic half-life,"The average biologic half-life for plasma-to-tissue equilibrium was 7 to 12 minutes, and the volume of distribution was 0.2 to 0.5 microL.mL(-1).",Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439293/),min,7 to 12,273181,DB00150,L-Tryptophan
,12439293,volume of distribution,"The average biologic half-life for plasma-to-tissue equilibrium was 7 to 12 minutes, and the volume of distribution was 0.2 to 0.5 microL.mL(-1).",Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439293/),[μl] / [ml],0.2 to 0.5,273182,DB00150,L-Tryptophan
